Well PF1066 is getting "strong regressions" in the clinic, which trumps any preclinical claims Aria might have.
Seems like the Aria drug has been kind of slow to an IND here. They've been talking about it for ages now.
But if it is indeed better than the PFE drug, we would be talking a very significant drug for a company this size. Again the type of magic drug that could in my view demonstrate approvability in a small Phase I trial.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.